ATLANTA, GA — (Globe Newswire – June 2, 2026) — Holzer & Holzer, LLC is investigating whether Fulcrum Therapeutics, Inc. (“Fulcrum” or the “Company”) (NASDAQ: FULC) complied with federal securities laws. On June 1, 2026, Fulcrum announced the discontinuation of its pociredir program for the treatment of sickle cell disease. The price of the Company’s stock dropped following this news.

If you purchased Fulcrum stock and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com/case/fulcrum-therapeutics/ to discuss your legal rights.